The Specter Of Spin-off Plans Dominates Pfizer Year-end Earnings
This article was originally published in The Pink Sheet Daily
Executive Summary
Although the company beat estimates and executed on an ambitious late-stage pipeline, analysts on Pfizer’s earnings call were focused on palbociclib, Prevnar, and the pharma’s plans for its established products business.